Kenneth Patrick Mulvany
Director/Board Member at BENEVOLENTAI
Net worth: 23 M $ as of 30/04/2024
Profile
Kenneth Patrick Mulvany is the founder of Proximagen Group Plc, which was founded in 2005.
He served as the Chief Executive Officer from 2005 to 2012.
He was also the founder of BenevolentAI Ltd., founded in 2015, where he held the title of Executive Chairman from 2015 to 2021.
Additionally, he was the founder of BenevolentAI SA, founded in 2013, where he served as a Non-Executive Director from 2013 to 2022.
Dr. Mulvany is also the founder of BenevolentAI.
Currently, he holds the position of Deputy Chairman at BenevolentAI SA since 2024 and has been a Director at BenevolentAI Bio Ltd.
since 2013.
He is also a Trustee at The Cure Parkinson's Trust.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
BENEVOLENTAI S.A.
23.78% | 31/12/2022 | 33,912,333 ( 23.78% ) | 23 M $ | 30/04/2024 |
Kenneth Patrick Mulvany active positions
Companies | Position | Start |
---|---|---|
BENEVOLENTAI | Director/Board Member | 02/05/2024 |
BenevolentAI Bio Ltd.
BenevolentAI Bio Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Bio Ltd. is a clinical-stage AI-enabled drug discovery and British development company founded in 2013. The company is based in London, UK. BenevolentAI Bio uses AI to augment scientific ingenuity in the drug discovery process, from target identification to clinical development, with the goal of improving the probability of clinical success. The company has refined and formalized its approach to sustainability under the direction of the newly established environmental, social, and governance (ESG) governance structure and teams. BenevolentAI Bio's AI-enabled Benevolent Platform™ empowers scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug. | Director/Board Member | 13/11/2013 |
The Cure Parkinson's Trust | Director/Board Member | - |
Former positions of Kenneth Patrick Mulvany
Companies | Position | End |
---|---|---|
BENEVOLENTAI | Founder | 30/06/2022 |
Minster Pharmaceuticals Plc
Minster Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Minster Pharmaceuticals Plc develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions. The company operates in Tonabersat and Sabcomeline segments. The Tonabersat segment is for the prevention and treatment of migraine. The Sabcomeline segment is for the management of cognitive decline and negative symptoms in schizophrenia. Minster Pharmaceuticals was founded by Robert Stubbs and Paul Sharpe in 2001 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
BenevolentAI Ltd.
BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Founder | - |
Proximagen Group Plc
Proximagen Group Plc Miscellaneous Commercial ServicesCommercial Services Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom. | Founder | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
BENEVOLENTAI | Health Technology |
Private companies | 5 |
---|---|
Proximagen Group Plc
Proximagen Group Plc Miscellaneous Commercial ServicesCommercial Services Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Minster Pharmaceuticals Plc
Minster Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Minster Pharmaceuticals Plc develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions. The company operates in Tonabersat and Sabcomeline segments. The Tonabersat segment is for the prevention and treatment of migraine. The Sabcomeline segment is for the management of cognitive decline and negative symptoms in schizophrenia. Minster Pharmaceuticals was founded by Robert Stubbs and Paul Sharpe in 2001 and is headquartered in London, the United Kingdom. | Health Technology |
BenevolentAI Bio Ltd.
BenevolentAI Bio Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Bio Ltd. is a clinical-stage AI-enabled drug discovery and British development company founded in 2013. The company is based in London, UK. BenevolentAI Bio uses AI to augment scientific ingenuity in the drug discovery process, from target identification to clinical development, with the goal of improving the probability of clinical success. The company has refined and formalized its approach to sustainability under the direction of the newly established environmental, social, and governance (ESG) governance structure and teams. BenevolentAI Bio's AI-enabled Benevolent Platform™ empowers scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug. | Technology Services |
BenevolentAI Ltd.
BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Technology Services |
The Cure Parkinson's Trust |
- Stock Market
- Insiders
- Kenneth Patrick Mulvany